Emerging from under the patent cliff, Big Pharma is still suffering from the burden of tighter regulation and reduced healthcare budgets, while investors are seeing declining growth and returns. The Pharma Summit 2013 -Back to Basics: The Real Business of Pharma, organised by The Economist Group, discussed how the industry is dealing with these problems.
展开▼
